Resources

Discover how an IQVIA study found Digital Companion users were significantly more likely to remain on therapy, providing new evidence for the impact of digital patient support.

From routine disruptions to symptom management, discover the factors that shape gastroenterology therapy persistence.

Nearly 30% of missed doses occur because patients don't believe treatment is necessary. Explore the behavioral drivers behind dermatology adherence.

New analysis of 12+ years of adherence data reveals the behavioral patterns, treatment factors, and support mechanisms that drive metabolic therapy persistence.

New analysis of millions of managed doses uncovers the behavioral patterns, treatment complexities, and engagement trends shaping cardiovascular therapy persistence.

Breast cancer remains one of the most prevalent malignancies worldwide, with an estimated 287,850 new invasive cases and 43,250 breast cancer–related deaths projected in the United States in 2025 (American Cancer Society, 2025). Despite advances in targeted oral therapies for extended adjuvant treatment, real‐world studies find that up to 50% of patients discontinue or skip doses, undermining efficacy (Mayo Clinic, 2024).

Leading pharmaceutical companies are now using AI to help healthcare providers simplify and streamline the patient experience for specialty medications, which can be difficult to access, adhere to, and afford.

For the 133 million Americans who live with a chronic condition, and the 81 million who have two or more conditions, managing medications is more than just taking a pill. It becomes a priority to maintaining good health and the ability to live an active and fulfilling life.

This article explores how Medisafe’s intelligent patient engagement platforms provide unparalleled value to pharmaceutical executives, from driving adherence to surfacing actionable insights, and how these offerings are setting new standards in digitally enabled patient care. Discover the technologies and trends poised to shape pharma’s next competitive advantage.

Medication non-adherence is a $300B issue that can impact the cost of prescription drugs, medical care, and lead to serious health risks. Unfortunately, without greater support, non-adherence can become commonplace especially among patients with chronic disease. But medication non-adherence is more than just skipping a dose or forgetting a refill.

Discover why patients skip doses, when patients are most likely to skip doses, and factors affecting these decisions.

Worldwide medication adherence rates for most neurology conditions average 78% on Medisafe

Here’s what today’s pricing development means for pharma brand marketers, patient support teams, innovation leads, access executives, and procurement leadership—and how Medisafe is uniquely positioned to drive higher adherence, long-term engagement, and ultimately better outcomes for those embarking on complex treatment journeys.